Contact Us Today

Back to Case Studies

IRA investing has brought more – and higher value – investors to InSitu Biologics’ capital raise. When InSitu Biologics, Inc. opened its Reg A+ pre-revenue equity offering to IRA investors in 2018, company President and CEO Jim Segermark quickly realized he was attracting new investors to the capital raise that wouldn’t have invested without the IRA option. Equally important, Segermark noted, is that the size of investments made by people using tax-advantaged IRAs through Equity Trust Company has been significantly larger, on average, than those investing with cash. Read the rest of the case study.

Request Free!

Free Biotechnology & Pharmaceuticals Magazines and Downloads from

, , , , , , , , , , , ,


Phone:855-400-8202 a division of PMHL
United States
2320 E Baseline Rd Suite 148-418
Phoenix, AZ 85042

XML Site Map
Sign up for newsletter
[newsletter_form form="1"]
Sign up for newsletter
[newsletter_form form="1"]

© 2006- 2017 PMH Tec All Rights Reserved